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Summary.-CEA immune complexes and free CEA were determined in 363 patients
with histologically confirmed adenocarcinoma of the gastrointestinal tract before
surgery and in a post-operative follow-up. Circulating CEA immune complexes
(CEA-IC) could be detected preoperatively in 89 patients. Incidence of CEA-IC
increased with increasing tumour extension; 72/89 patients with CEA-IC showed
already metastatic disease progression, 40/89 had nonresectable tumours. Patients
with preoperative CEA-IC had a poorer prognosis than patients without CEA-IC but
with high levels of free CEA, or CEA-negative patients. The appearance of CEA-IC
with consecutive increases in the postoperative follow-up indicated disease recur-
rence. In 32/55 relapse cases, circulating CEA-IC were detected postoperatively, all
32 cases developing metastatic spread of disease.
ANTIBODIES reacting with carcinoem-
bryonic antigen (CEA) have originally
been demonstrated in patients with non-
metastatic digestive-system cancers and
in pregnant women by Gold (1967) using
an indirect haemagglutination technique.
After the development of highly sensitive
radioimmunoassay methods the existence
of circulating anti-CEA antibodies could
be confirmed (Gold et al., 1972; McSween,
1975). Evidence for the presence of CEA
immune complexes (CEA-IC) in glomeru-
lar deposits has been given for a case of
colonic carcinoma with nephrotic syn-
drome (Costanza et al., 1973) as well as for
a case of pancreatic carcinoma where a
complex containing immunoglobulin M
and a CEA cross-reacting component
could be isolated from the ascitic fluid
(Harvey et al., 1978). Recently, it was also
shown that the sera of patients with
gastrointestinal (GI) cancer contained a
fraction of CEA-IC in which CEA was
bound to IgM and partly also to IgG, and
which could be separated from the free
CEA. The binding of CEA to IgM and
IgG was demonstrated by displacement
experiments with a radioactive CEA
marker using radioimmunodiffusion. Free
CEA-binding immunoglobulins could not
be detected (Kapsopoulou-Dominos &
Anderer, 1979a).
In the last decade there was con-
troversy about the autoantigenicity of
CEA. Various groups using different tech-
niques were unable to confirm the exist-
ence of circulating anti-CEA antibodies
(Collatz et al., 1971; LoGerfo et al., 1972;
Sorokin et al., 1973). One group, however,
could demonstrate circulating antibodies
against NCA (nonspecific cross-reacting
antigen), a glycoprotein present in normal
human tissue and strongly cross-reacting
with CEA by means of a "common site"
antibody (Von Kleist et al., 1972, 1978).
The authors stressed the point that anti-
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CEA antibodies might be specific anti-
bodies against NCA.
Antibodies, specific for CEA or NCA, in
the presence of antigen excess should be
found predominantly in the fraction of
immune complexes. The detection of CEA
immune complexes in sera ofpatients with
gastrointestinal cancer (Kapsopoulou-
Dominos & Anderer, 1979a) provokes the
question whether these complexes may
block tumour-cell destruction by immune
lymphocytes, thus enhancing tumour
growth. Evidence that "blocking anti-
bodies" are antigen-antibody complexes
has been given by several groups (Sjogren
et al., 1971; Baldwin et al., 1972; Jose &
Seshadri, 1974).
In our present study, performed in the
years 1976 to 1979, we examined the
possible correlation of preoperative CEA-
IC with the degree of tumour extension,
the postoperative changes of the amount
of CEA bound to immunoglobulins during
a 3-year follow-up study and the survival
rate of patients with CEA-IC. We used a
routine determination of CEA bound to
immunoglobulins (Kapsopoulou-Dominos
& Anderer 1979b) whichis based onthe fact
that immune complexes are precipitated
together with the bulk ofother serum pro-
teins when perchloric acid is added to the
serum. CEA present in the perchloric acid
precipitates was found to be bound to
IgM and IgG, which could be demon-
strated in radioimmunological displace-
ment experiments. The amount of CEA
corresponded fairly well to that obtained
by column fractionation (Kapsopoulou-
Dominos & Anderer, 1979a,b).
MATERIALS AND METHODS
Patients and sera. 363 patients (m/f= 1.5)
were registered for a follow-up of the serum
concentrations of free CEA and CEA bound
in immune complexes. All patients were
treated by surgery and had histologically
proven adenocarcinomata of the rectum
(80), colon (120), stomach (144) or pancreas
(19). For the characterization of the extent
of the tumours, we used the TNM clas'sifica-
tion of the International Union Against
Cancer (1978).
Sera were obtained from blood samples
taken a few days before and 8-10 days after
operation, and thereafter at intervals of 2-3
months.
Radioimmunoassay.-The concentration of
free CEA in the sera was determined after
perchloric acid extraction by the Hansen
Z-gel method (Hansen et al., 1971) using the
CEA-Roche RIA test kit (Roche Diagnostics,
Basel, Switzerland). Variations in the anti-
CEA serum batches of the CEA Roche RIA
test kit were controlled on the basis of our
own internal CEA standards.
The CEA-IC were found exclusively in
the perchloric-acid precipitate (Kapsopoulou-
Dominos&Anderer, 1979b) provided thatdilu-
tion ofthe original serum (0.5ml+2 ml saline)
addition ofperchloric acid and sedimentation
of the resulting precipitate (2500 g, 20 min)
was carried out without delay. After removal
of the perchloric-acid extracts the amount of
CEA bound in immune complexes was deter-
mined in the perchloric-acid sediment as
follows: The wall of the test tube containing
the sediment obtained from 0 5 ml of original
serum, wras gently rinsed with 5 ml H20
without perturbing the sediment. The super-
natant fluid was decanted and the sediment
dissolved in 2ml 2M Tris solution yielding
about pH 9-5. Thereafter, an aliquot of0 5 ml
was brought to 5 ml by adding saline and
dialysed against O-O1M ammonium acetate
(pH 6 8) followed by determination of CEA
with the Roche RIA test without further
perchloric-acid treatment. The sensitivity
ofthe approach for the determination ofCEA-
IC was mainly limited by the criteria of the
CEA Roche-RIA test. The lower limit for
reproducible determinations of CEA in the
perchloric-acid sediment was found to be
3.5 ng/ml original serum.
Optimal separation of free CEA and CEA-
IC by perchloric-acid precipitation was
dependent on the overall protein concentra-
tion of the serum. Sera with a high level of
free CEA were prediluted with an adequate
control serum before precipitation of the
CEA-IC with perchloric acid, since predilution
with buffer alone yielded a decreased amount
of perchloric-acid precipitate, and also a
decreased amount of CEA-IC in the pre-
cipitates, possibly due to formation of acid-
soluble complexes (Kapsopoulou-Dominos &
Anderer, 1979b). Control sera contained no
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CEA-IC and were generally obtained from
healthy persons.
Perchloric-acid precipitation ofthe CEA-IC
together with the bulk of serum proteins
includes the risk ofunspecific co-precipitation
and inclusion of free CEA in the precipitate.
In a separate study this possibility was
investigated, using undiluted sera which con-
tained various concentrations of exogenous
CEA and radioiodinated CEA (1 ng) as a
marker. The amount of free CEA in the per-
chloric-acid precipitates varied between 3 and
10% at all CEA concentrations between 30
and 1000 ng CEA/ml serum. These findings
gavethebasisfor a correction oftheamount of
CEA bound in immune complexes present in
perchloric acid precipitates.
In our control sera the intra-assay variance
(1 a) for the determination of free CEA was
4-8 +0 4 ng/ml serum and of complex bound
CEA 4.5 + 1-3 ng/ml serum.
RESULTS
Incidence of preoperative CEA immune
complexes
Circulating CEA-IC were detected in 89
of 363 patients with histologically proven
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adenocarcinoma of the GI tract. All of
these 89 patients also had a high serum
concentration offree CEA, except 13 with
a free CEA level less than 2 ng/ml serum.
In Fig. 1 the preoperative values of free
CEA (abscissa) and the values of CEA-IC
(ordinate) are given in a double logarith-
mic plot for each patient. Patients (111/
363) with neither free CEA levels > 2 ng/
ml nor CEA bound in immune complexes
> 3.5 ng CEA/ml were not listed. Among
the CEA+ patients we observed cases with
very high concentrations of free CEA and
no CEA-IC as well as cases with low values
offree CEA and a high amount ofCEA-IC.
To answer the question whether the
presence of circulating CEA-IC before
surgery has any clinical relevance to the
prognosis of the patients we tried to
correlate a set of clinical parameters with
the following 3 categories of preoperative
CEA concentrations: (1) free CEA < 2 ng/
ml and no detectable CEA-IC; (2) free
CEA high but no detectable CEA-IC;
(3) CEA-IC present. As clinical parameters
we used location of the primary tumour,
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FIG. 1.-Double logarithmic plot of the preoper*ttive eQncentration of free CEA V8. CEA bound
in immune complexes (CEA-IC) for individual pstient$ with histologically proven adenocarcinoma
of the gastrointestinal (GI) tract. Values of CFEA-IC are corrected for unspecific coprecipitation
of 10% of the free CEA.
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TABLE.-Correlation of the clinical status ofpatients with adenocarcinoma
with preoperative levels offree CEA and CEA-IC
Patients with ng free CEA/ng CEA-IC/ml serum
Location ofthe primary carcinoma
Rectum
Colon
Sigmoid colon
Stomach
Pancreas
Total
Tumour extent (TNM)
T60, N,M=0
T,N$0; M=0
M =1
Total
of the GI tract
tA % with
<2/< 3-5 > 2/ < 3-5 any > 3-5 Total CEA-IC
19
11
26
53
2
42
23
27
63
8
111 163
54
45
9
62
65
34
108 161
19
9
24
28
9
80
43
77
144
19
24
21
31
19
47
89 363
17
31
41
133
141
84
13
22
49
89 358
Surgical treatment
Palliative
Nonresectable
36
6
Age distribution
<60
60-70
>70
28
43
40
62
29
40
55
68
32 130
40 75
22
33
34
90
131
142
Total 111 163
tumour extent according to the TNM
classification, surgical treatment (pallia-
tive or nonresectable) and age distribu-
tion. The corresponding data are system-
atically listed in the Table. The most
interesting result was that the portion of
patients with circulating CEA-IC in-
creased with increasing tumour extent.
In about half the cases with widespread
tumour growth (M = 1) and nonresectable
tumours, CEA-IC could be detected pre-
operatively. This portion was 4 x that in
the cases with local tumours without
lymphnode metastasis. In the group of 17
patients with resectable tumours and
circulating CEA-IC, 2 cases staged T 1,
4 cases T 2, 5 cases T 3 and 6 cases T 4
were recorded. 68/75 cases with non-
resectable tumours were staged T 4,
mostly with metastases. The location of
the primary tumours appeared to have no
significant influence on the incidence of
CEA-IC, except for carcinoma of the
pancreas. Furthermore, the presence of
preoperative CEA-IC was independent of
age.
89 363
Survival of patients with preoperative
CEA-IC
All of our 363 patients now have a
follow-up of free CEA and CEA-IC for at
least 2 years, and some for more than
3 years. A comparison of the survival of
patients after surgery yields more de-
tailed information on the prognosis of
these patients. We selected 3 sub-
groups specified by the following pre-
operative CEA criteria: (1) patients with
CEA-IC; (2) patients with high levels of
free CEA but with no detectable circu-
lating CEA-IC; (3) CEA- patients. The
survival curves in Fig. 2A show that
patients with stomach cancer and pre-
operative CEA-IC have a poor prognosis,
with a half life of about 120 days after
surgery, compared with patients with only
high levels offree CEA (halflife 300 days)
and patients with neither high free CEA
nor CEA-IC (600 days), The survival
curves of patientp with colorectpl cancer
(Fig. 2B) indicatte a distinctly better
prognosis. Even when CEA-IC 'could be
detected preopeiatively, this group of
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FIG. .2.-Survival curves of patients with histologically proven adenocarcinoma of the GI tract and
with the following preoperative CEA criteria: 0-0 patients with neither high, levels of free
CEA nor CEA-IC; 0-0 patients with no CEA-IC but high levels of free CEA; A-A patients
with CEA immune complexes. A: Patients with carcinoma of the stomach; B. patients with colo-
rectal carcinoma.
patients showed a half life of about 420
days, and the group with only high levels
of free CEA, about 720 days.
The survival curves of patients with
only pathological concentrations of free
CEA were significantly different from
those ofCEA- patients in the range of 300
to 1200 days in cases with stomach cancer,
and in the entire range of postoperative
surveillance in cases with colorectal can-
cer. Significant differences in survival
between patients with CEA-IC and with
patients with only pathologically high
levels offree CEA were obtained up to 720
days in cases with stomach cancer, and in
the range between 180 and 840 days in
cases with colorectal cancer.
Postoperative follow-up of free CEA and
CEA-IC
In this part ofthe study we investigated
the appearance of circulating CEA-IC as
a marker for early detection of disease
recurrence. Only patients who underwent
curative resection as judged from the
situs and the results of the histological
examination were subject ofthe follow-up.
Therefore this group excludes most of the
patients with preoperatively detectable
CEA-IC, who predominantly had non-
resectable' tumours (40/89) or received
only palliative treatment (32/89).
Inthegroupof158patientswithcurative
resections we have had up to date 57
cases of disease recurrence with con-
secutively increasing levels of free CEA.
CEA-IC were detected in the sera of 34/57
patients up to 9 months before clinical
diagnosis was possible (4/17 patients with
primary resection of stomach cancer,
29/39 with primary colorectal cancer, 1/1
with pancreatic cancer). All 9 patients
with local recurrence had no detectable
circulating CEA-IC (5 patients with
stomach cancer, 4 with colorectal cancer).
Patients with detectable CEA-IC always
had distant metastatic spread. In Fig. 3
the time course of free CEA and CEA-IC
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FIG. 3. CEA surveillance diagram of a
73-year-old female with an extirpated
adenocarcinoma of the rectum who de-
veloped a localized recurrence 14 months
after surgery. After successful second-look
surgery the patient remained free ofdisease
forfurther 16months, when aperitoneal car-
cinosis was diagnosed, accompanied by in-
creases in free CEA (broken line) and CEA-
IC (solid line). -
is given for a case with a resected primary
carcinoma of the rectum and second-look
surgery for a local recurrence. The patient
had no CEA-IC until 30 months after the
second-look operation, when the patient
developed a peritoneal carcinosis. It is
noteworthy that the time course of CEA-
IC in cases with recurrent disease did not
always parallel the course of free CEA. In
7/32 cases of disease recurrence and
detectable CEA-IC the amount of com-
plex-bound CEA was distinctly higher
than the amount of free CEA, 2-6 months
before clinical diagnosis, partly immedi-
ately after primary resection (2 stomach
cancer, 5 colorectal cancer).
We also found intermediate increases of
CEA-IC up to 2 months after surgery, not
necessarily linked to a simultaneous in-
crease of free CEA, which were usually
found in cases with lymphnode metastasis.
Sometimes, similar intermediate increases
later in the follow-up could also be de-
tected, for instance, in 9 cases with
resected primary carcinomas of the
stomach and rectum and a temporary
infection of the urological tract.
In the course of our study, 100 patients
with far-advanced tumour growth could
be followed up to death by serial deter-
minations of CEA-IC and free CEA. In
this group 510% of the patients had
months - 10 20
FiG. 4.-CEA surveillance diagram of an
82-year-old malewith resectedstomach can-
cer who developed a peritoneal carcinosis
with a rapid increase of CEA-IC (solid line)
followed by a sudden decrease to zero
before death (free CEA: broken line).
steadily increasing amounts of CEA-IC
several months before death; 39% of
these patients died during that phase of
increase and 12% showed a dramatic
decrease shortly before death, without an
analogous change in the concentration of
free CEA. In Fig. 4 the follow-up diagram
is given for a patient who had only
palliative treatment of a primary carcin-
oma of the stomach and developed a
peritoneal carcinosis. The CEA-IC started
to increase 4 months after surgery and
dropped to zero after 18 months, possibly
due to the beginning of immunological
anergy. The patient died 25 months after
operation without a significant change of
the level of free CEA.
The time courses of free CEA in this
group of patients showed in 76% of cases
a steady, in some cases dramatic increase
of free CEA in the final phase, and in the
remainder no significant changes in the
concentration offree CEA before death.
DISCUSSION
The data obtained in our study indicate
that the preoperative detection of circu-
lating CEA-IC can be used as a prognostic
marker in patients with adenocarcinoma
of the GI tract. At the time of primary
resection sera of 89/363 patients contained
detectable amounts of CEA-IC and 72 of
these 89 patients already showed meta-
static disease progression, as judged from
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the situs and the histological examina-
tions. The postoperative survival curves
of the patients with preoperative CEA-IC
agree with a poorer prognosis than that of
patients who had only high levels of free
CEA. In addition, the appearance of
circulating CEA-IC in the postoperative
follow-up also indicates a poor prognosis,
i.e. all patients with CEA complexes
developed metastatic disease. In some
cases the increase of CEA-IC occurred
before the increase of free CEA.
The mechanism by which circulating
CEA-IC areinfluencing diseaseprogression
can be interpreted in terms of "immune
lymphocyte blocking" and enhancement
of tumour growth, as had been reported
for other systems by several groups
(Sjogren et al., 1971; Baldwin et al., 1972;
Jose & Seshadri, 1974). Preliminary
studies by us with a limited number of
patients indicate that in about 20% ofthe
cases CEA-specific lvmphocyte cytotoxi-
city can be blocked with CEA-IC (work
in progress). This mechanism need not be
unique, since metastatic disease pro-
gression was also seen without detectable
amounts of CEA-IC. On the other hand,
one has to bear in mind that our method
of detecting CEA-IC is restricted to the
serum, and is possibly not sensitive
enough to detect trace amounts which
might be ofimmunological relevance.
The mechanism of induction of anti-
CEA antibodies cannot be substantiated
on the basis of our present knowledge.
Autoantigenicity of CEA is suggested by
the fact that the presence of circulating
CEA-IC is predominantly associated with
metastatic disease progression, which
could be understood in terms of enhance-
ment of tumour growth by "immune
lymphocyte blocking", and by analogy
with a number of reports which have
already demonstrated that animals bear-
ing very different tumours have mounted
an immune response not only against
tumour-specific antigens but also against
embryonic components (Baldwin et al.,
1974; Baldwin & Embleton, 1974; Steele
et al., 1975; Zoller et al., 1976; Tagliabue
et al., 1979). An alternative explanation
resides in the possibility that the forma-
tion ofCEA-IC is a result ofcross-reacting
antibodies. However, autoantibodies
against NCA (Collatz et al., 1971; Von
Kleist & Burtin, 1966) seem not to be
involved, since increases in the concentra-
tion of NCA are of less clinical value in
indicating tumour progression than those
of CEA (Von Kleist et al., 1977). This
would most likely also apply to NCA
immune complexes. On the other hand
NCA-specific antibodies should preferably
bind to NCA which is present in a many-
fold excess in the serum as compared to
CEA (Von Kleist et al., 1977) and accord-
ing to the expected affinity of these anti-
bodies all free NCA should be bound in
complexes before CEA complexes are
formed.
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